Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Author contributions
  • Conflict of interest
  • Funding support
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research ArticleNeuroscienceOncology Open Access | 10.1172/JCI201808

Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity

Daozhong Jin, Hong Chen, Yuying Huang, Shao-Rui Chen, and Hui-Lin Pan

Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Hui-Lin Pan or Shao-Rui Chen, Department of Anesthesiology and Perioperative Medicine, Unit 110, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 832.817.8447; Email: huilinpan@mdanderson.org (HLP); schen@mdanderson.org (SRC).

Find articles by Jin, D. in: PubMed | Google Scholar

Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Hui-Lin Pan or Shao-Rui Chen, Department of Anesthesiology and Perioperative Medicine, Unit 110, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 832.817.8447; Email: huilinpan@mdanderson.org (HLP); schen@mdanderson.org (SRC).

Find articles by Chen, H. in: PubMed | Google Scholar

Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Hui-Lin Pan or Shao-Rui Chen, Department of Anesthesiology and Perioperative Medicine, Unit 110, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 832.817.8447; Email: huilinpan@mdanderson.org (HLP); schen@mdanderson.org (SRC).

Find articles by Huang, Y. in: PubMed | Google Scholar

Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Hui-Lin Pan or Shao-Rui Chen, Department of Anesthesiology and Perioperative Medicine, Unit 110, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 832.817.8447; Email: huilinpan@mdanderson.org (HLP); schen@mdanderson.org (SRC).

Find articles by Chen, S. in: PubMed | Google Scholar

Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Hui-Lin Pan or Shao-Rui Chen, Department of Anesthesiology and Perioperative Medicine, Unit 110, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 832.817.8447; Email: huilinpan@mdanderson.org (HLP); schen@mdanderson.org (SRC).

Find articles by Pan, H. in: PubMed | Google Scholar

Published July 14, 2026 - More info

Published in Volume 136, Issue 17 on September 1, 2026
J Clin Invest. 2026;136(17):e201808. https://doi.org/10.1172/JCI201808.
© 2026 Jin et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 14, 2026 - Version history
Received: December 23, 2025; Accepted: July 2, 2026
View PDF
Abstract

Opioids are essential analgesics for managing severe pain but can paradoxically increase pain sensitivity (hyperalgesia) and diminish analgesic efficacy (tolerance). Hyperactivity of NMDA-type glutamate receptors (NMDARs) at primary afferent terminals in the spinal cord contributes to both phenomena; however, the underlying signaling mechanisms remain unclear. Here, we report that morphine administration in rats promoted the translocation of monomeric BRAF, an oncogenic kinase, from the dorsal root ganglion (DRG) to spinal cord synaptosomes, leading to increased MEK-ERK phosphorylation at nociceptor central terminals. BRAF physically interacted with NMDARs in both rat and human spinal cords. Inhibition of BRAF activity with vemurafenib reversed morphine-induced NMDAR phosphorylation and synaptic localization of α2δ-1–bound NMDARs. Vemurafenib also abolished morphine-induced presynaptic NMDAR hyperactivity in spinal dorsal horn neurons. Correspondingly, conditional Braf knockout in DRG neurons normalized morphine-enhanced NMDAR phosphorylation, synaptic trafficking of α2δ-1–bound NMDARs, and NMDAR hyperactivity in the spinal cord. Furthermore, pharmacological inhibition of BRAF or MEK, or Braf deletion in DRG neurons, enhanced morphine analgesia while mitigating morphine-induced hyperalgesia and tolerance. These findings identify BRAF overactivity at nociceptor central terminals as a key mediator of opioid-induced NMDAR hyperactivity. Clinically approved BRAF inhibitors could be repurposed to enhance opioid analgesia while minimizing adverse effects.

Graphical Abstract
graphical abstract
Introduction

Opioids remain the most potent and indispensable analgesics for managing moderate to severe pain resulting from major surgery, trauma, and cancer. Paradoxically, opioid treatment can lead to a progressive increase in pain sensitivity (hyperalgesia) alongside a reduction in analgesic efficacy (tolerance) (1–3). Notably, even acute exposure to opioids such as morphine and fentanyl can produce long-lasting hyperalgesia in both animal models and humans (4–8). These maladaptive responses often drive unsafe dose escalation, increasing the risk of dependence, addiction, and overdose death. A major challenge in pain control is identifying the signaling pathways that mediate the shift in opioid effects from analgesia to hyperalgesia in vivo. μ-Opioid receptors (MORs), which mediate opioid analgesia, are abundantly expressed in dorsal root ganglion (DRG) neurons and their central terminals in the spinal dorsal horn (9, 10). Targeted deletion of MORs in DRG neurons eliminates both the inhibitory and excitatory effects of opioids on spinal nociceptive transmission, thereby diminishing the analgesic and hyperalgesic effects of systemically administered opioids (11–13). These findings highlight the critical importance of elucidating the signaling mechanisms operating at sensory neuron–dorsal horn neuron synapses that govern the shift in opioid actions from inhibition to excitation.

MOR activation induces sustained hyperactivity of N-methyl-D-aspartate receptors (NMDARs) at primary afferent terminals in the spinal cord, playing a crucial role in opioid-induced hyperalgesia and tolerance (1, 3, 12, 14–16). NMDARs at primary afferent terminals in the spinal dorsal horn are normally quiescent due to intracellular retention by LRRC8A proteins (17). However, short- and long-term use of opioids promotes NMDAR synaptic trafficking and hyperactivity, amplifying nociceptive transmission (3, 12, 16). NMDAR phosphorylation is a key event driving this synaptic localization and hyperactivity in the spinal cord (3, 18–20). This phosphorylation is typically mediated by protein kinase C (PKC) through cross-talk between MORs and Gαq signaling (3, 20). Additionally, opioids activate extracellular signal-regulated kinase (ERK) in cultured cells transfected with MORs (21–26), and ERK activation contributes to NMDAR hyperactivity in both the brain and spinal cord (18, 27). Pharmacological inhibition of ERK reduces opioid-induced NMDAR hyperactivity, hyperalgesia, and tolerance (18). However, the mechanisms by which opioids activate ERK remain unclear. Currently, neither PKC nor ERK inhibitors are used clinically due to intolerable adverse effects, underscoring the need for alternative, clinically viable kinase targets to mitigate opioid-induced hyperalgesia and tolerance.

RAF (rapidly accelerated fibrosarcoma) kinases are serine/threonine-specific enzymes that function upstream of mitogen-activated protein kinase kinases (MEK) and ERK signaling pathway. The RAF family comprises three isoforms: ARAF, BRAF, and CRAF (also known as RAF-1). Notably, BRAF, but not CRAF, regulates ERK phosphorylation in neurons (28). BRAF is the only RAF kinase highly enriched at synapses and distributed throughout neuronal somas and processes (29), whereas CRAF is largely confined to the perinuclear cytosol (30). Although BRAF is most recognized for its role in oncogenesis, particularly through activating mutations like BRAFV600E (31, 32), its synaptic localization and involvement in G-protein signaling (29, 33, 34) suggest that it may serve as a critical link between MOR activation and synaptic NMDAR phosphorylation and hyperactivity. However, its neuronal and synaptic functions remain largely unexplored.

In this study, we investigated whether BRAF signaling contributes to opioid-induced NMDAR phosphorylation and hyperactivity at spinal sensory synapses. We demonstrated that opioid treatment promoted BRAF recruitment to primary afferent terminals in the spinal cord, thereby increasing its activity through MEK-ERK signaling. BRAF inhibition or genetic ablation in DRG neurons attenuated opioid-induced hyperalgesia and tolerance by suppressing NMDAR phosphorylation, synaptic localization, and hyperactivity at nociceptor central terminals. By identifying overactive BRAF as a key mediator of opioid-induced nociceptive plasticity, our findings suggest that BRAF inhibitors currently used in oncology could be repurposed to improve opioid analgesic efficacy while minimizing adverse effects.

Results

BRAF is expressed in DRG neuron subtypes and spinal cord. BRAF is present in the DRG and spinal cord (28, 35). To characterize the cellular distribution of BRAF, we performed double immunofluorescence labeling in the rat DRG and spinal dorsal horn. Immunofluorescence analysis revealed that BRAF immunoreactivity in the DRG colocalized with NF200, CGRP, and IB4 (Figure 1A), markers of large-diameter neurons, small-diameter peptidergic neurons, and small-diameter nonpeptidergic neurons, respectively. Among BRAF-positive neurons, approximately 35% coexpressed NF200 (38.35 ± 3.46%) or IB4 (33.50 ± 2.04%), whereas about 28% were CGRP-positive (28.16 ± 3.60%). In the spinal cord, BRAF immunoreactivity was distributed throughout the dorsal horn, with particularly dense labeling in laminae I and II. Colocalization with the neuronal marker NeuN confirmed that BRAF was expressed in neurons of the spinal dorsal horn (Figure 1B).

Spatial distribution of BRAF in DRG neuron subtypes and spinal dorsal horn.Figure 1

Spatial distribution of BRAF in DRG neuron subtypes and spinal dorsal horn. (A) Representative immunofluorescence images show colocalization of BRAF (green) with NF200, IB4, or CGRP (red) in the rat DRG. (B) Representative immunofluorescence images show colocalization of BRAF (green) with NeuN (red) in the rat spinal dorsal horn. Scale bar: 50 (A), 100 (B, bottom row), or 200 (B, top row) μm.

Opioid treatment promotes BRAF protein translocation from the DRG to the spinal cord. BRAF is a critical kinase in the MAPK/ERK pathway, and its constitutive activation in nonneuronal cells drives cancer progression by amplifying growth-promoting signaling (36, 37). To determine whether opioid treatment influences BRAF expression, lumbar DRG and dorsal spinal cord tissues were collected from rats treated with saline or morphine (5 mg/kg, i.p., twice daily) for 3 or 7 consecutive days. Immunoblotting analysis detected a single BRAF protein band (approximately 85 kDa) in both tissues. Remarkably, morphine treatment for either 3 or 7 days substantially reduced BRAF protein abundance in the DRG compared with saline-treated controls (Figure 2, A–C). In contrast, total BRAF expression in the spinal cord was unchanged; however, BRAF abundance was markedly increased in the synaptosomal fraction following 3 or 7 days of morphine treatment (Figure 2, A–C). Real-time PCR analysis showed that morphine treatment for 7 days did not alter Braf mRNA levels in either the DRG or spinal cord (Figure 2D).

Morphine treatment promotes BRAF protein trafficking from the DRG to spinalFigure 2

Morphine treatment promotes BRAF protein trafficking from the DRG to spinal cord. (A–C) Representative immunoblot images (A, B) and quantification (C) show the effect of morphine treatment on the total and synaptosomal (Syn) BRAF protein amount in the DRG and spinal cord (SC). Total and synaptosomal proteins were extracted for immunoblotting analysis (n = 6–8 rats per group). GAPDH, β-actin, and PSD95 were used as loading controls on the same membranes. The lumbar DRG and dorsal spinal cord were collected from rats treated with morphine (5 mg/kg) or saline twice daily for 3 or 7 days. (D) Real-time PCR analysis shows the effect of morphine treatment on Braf mRNA expression in the DRG and spinal cord. Total RNA was extracted for real-time PCR analysis, with β-actin as the reference control (n = 6 rats per group). Data are expressed as means ± SEM. **P < 0.01, ***P < 0.001 (2-tailed Student’s t test).

To determine whether MOR activation is required for morphine-induced BRAF translocation from the DRG to the spinal cord, rats received a single intrathecal treatment with β-funaltrexamine (FNA, 10 μg), an irreversible MOR antagonist (38), or vehicle followed by morphine treatment (5 mg/kg, i.p., twice daily) for 7 days. As expected, repeated morphine administration in vehicle-treated rats induced mechanical and thermal hyperalgesia as well as analgesic tolerance, evidenced by a progressive reduction in baseline withdrawal thresholds and latencies and a gradual decline in morphine analgesic efficacy. Pretreatment with FNA diminished the development of morphine-induced hyperalgesia and tolerance (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI201808DS1). Moreover, acute morphine injection (5 mg/kg, i.p.) failed to produce analgesic effects on either day 1 or day 7 in FNA-treated rats (Supplemental Figure 1B). Importantly, FNA pretreatment also blocked morphine-induced changes in BRAF expression in the DRG and spinal synaptosomal fractions (Supplemental Figure 1C). Together, these data indicate that morphine treatment promotes MOR-dependent anterograde trafficking of BRAF from DRG neurons to their central terminals in the spinal cord.

Morphine treatment increases BRAF activity in the spinal cord but not DRG. To assess BRAF activity, we measured phosphorylation of MEK, a downstream substrate of BRAF. MEK phosphorylation at Ser217/Ser221 is essential for catalytic activation (39). Vemurafenib is a clinically used selective BRAF inhibitor that suppresses both mutant V600E and WT BRAF, with IC50 values of 31 nM and 100 nM, respectively (40). Rats received saline, morphine (5 mg/kg, i.p.) + vehicle, or morphine + vemurafenib (10 mg/kg, i.p.), twice daily for 7 days. In the DRG, the total MEK1/2 and pMEK1/2 amounts were comparable across all groups (Figure 3A). In contrast, morphine treatment increased pMEK1/2, but not total MEK1/2, levels in the spinal cord (Figure 3A). Cotreatment with vemurafenib reversed this morphine-induced increase in pMEK1/2 abundance in the spinal cord (Figure 3A). Vemurafenib alone had no effect on basal MEK1/2 or pMEK1/2 levels in either the DRG or spinal cord tissues (Figure 3B). Similarly, morphine treatment did not change total ERK1/2 or pERK1/2 levels in the DRG but increased pERK1/2 levels in the dorsal spinal cord (Figure 3C). Cotreatment with vemurafenib did not affect total ERK1/2 or pERK1/2 levels in the DRG but reversed the morphine-induced increase in pERK1/2 levels in the spinal cord (Figure 3C).

Treatment with morphine enhances BRAF activity in the spinal cord.Figure 3

Treatment with morphine enhances BRAF activity in the spinal cord. (A) Representative immunoblot images and quantification show the abundance of pMEK and total MEK in the DRG and dorsal spinal cord from rats treated with saline, morphine (M, 5 mg/kg) + vehicle (Veh), or morphine + vemurafenib (VEM, 10 mg/kg) twice daily for 7 days. Total proteins from lumbar DRGs and dorsal spinal cords were extracted for immunoblotting analysis of pMEK and MEK (n = 6 rats per group). (B) Representative immunoblot images and quantification showing the effect of vemurafenib on pMEK and total MEK expression in the DRG and dorsal spinal cords. Rats were treated with vehicle or vemurafenib (10 mg/kg, i.p.) twice daily for 7 days (n = 6 rats per group). (C) Representative immunoblot images and quantification show the abundance of pERK and total ERK expression in the DRG and dorsal spinal cords of rats treated with saline, morphine (M) + vehicle (Veh), or morphine + vemurafenib (VEM). Total proteins from lumbar DRGs and dorsal spinal cords were extracted for immunoblotting analysis of pERK and ERK (n = 6 rats per group). (D) Representative immunoblot images and quantification show the amount of phosphorylated MEK1 (pMEK) in BRAF immunoprecipitates from the spinal cord of rats treated with saline, morphine (M) + vehicle (Veh), or morphine + vemurafenib (VEM). Total proteins extracted from lumbar spinal cords were immunoprecipitated with a BRAF antibody, and the precipitated BRAF was incubated with recombinant MEK1 protein to assess MEK phosphorylation (n = 7 rats per group). Data are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Statistical significance was determined by 2-tailed Student’s t test in B and by 1-way ANOVA followed by Tukey’s post hoc test in A, C, and D.

To directly measure spinal BRAF kinase activity augmented by opioid treatment, we immunoprecipitated BRAF proteins from the dorsal spinal cord of rats treated with saline, morphine + vehicle, or morphine + vemurafenib. The precipitated BRAF protein was then incubated with recombinant polyhistidine-tagged MEK1 protein (45 kDa) in a phosphorylation reaction system to induce MEK1 phosphorylation. MEK1 is a preferred substrate of BRAF and responds rapidly to extracellular stimuli (41). The basal phosphorylation level of recombinant MEK1 (pMEK1) induced by BRAF from saline-treated rats was low (Figure 3D). The pMEK1 level in the spinal cord from the morphine + vehicle group was substantially higher and was normalized by cotreatment with vemurafenib. Notably, the total BRAF and MEK1/2 protein levels in the spinal cord tissues (input) were comparable among the 3 groups (Figure 3D). These findings collectively indicate that opioid treatment increases BRAF activity in the spinal cord and that vemurafenib is effective in inhibiting this opioid-induced neural BRAF overactivity.

BRAF mediates morphine-induced NMDAR phosphorylation in the spinal cord. Increased NMDAR phosphorylation in the spinal cord plays a key role in opioid-induced tolerance and hyperalgesia (19, 20). We next determined whether BRAF activity is involved in opioid-induced NMDAR phosphorylation in the spinal cord. To this end, lumbar dorsal spinal cords were collected from rats treated for 7 days with saline, morphine + vehicle, or morphine + vemurafenib. Total proteins were extracted and subjected to immunoprecipitation with a phosphoserine (pSer) antibody, followed by immunoblotting for GluN1, an obligatory NMDAR subunit (42). A single GluN1 protein band was detected in the immunoprecipitates by the pSer antibody, but not by irrelevant IgG control. Compared with saline control, morphine treatment markedly increased GluN1 levels in the pSer precipitates (Figure 4A), indicating enhanced GluN1 serine phosphorylation. Furthermore, cotreatment with vemurafenib strongly inhibited this morphine-induced increase. In contrast, the total GluN1 levels in input lysates did not differ among the 3 groups (Figure 4A). These results suggest that BRAF activity is involved in morphine-induced NMDAR phosphorylation in the spinal cord.

BRAF activity mediates morphine-induced NMDAR phosphorylation and synapticFigure 4

BRAF activity mediates morphine-induced NMDAR phosphorylation and synaptic trafficking of α2δ-1–NMDAR complexes in the spinal cord. (A) Representative immunoblot images and quantification of serine-phosphorylated (pSer) GluN1 in the spinal cord (n = 6 rats per group) of rats treated with saline, morphine (M) + vehicle (Veh), or morphine + vemurafenib (VEM). (B) Representative immunoblot images and quantification show that BRAF interacted with GluN1, but not μ-opioid receptor (MOR), in the synaptosomal fraction of the spinal cord (n = 6 rats per group) from rats treated with saline (Sal) or morphine (Mor). (C) Representative immunoblot images and quantification show the protein amount of α2δ-1, GluN1, and α2δ-1–GluN1 complexes in the spinal cord synaptosome from rats (n = 6 rats per group) treated with saline, morphine (M) + vehicle (Veh), or morphine + vemurafenib (VEM). Total and synaptosomal proteins were extracted from the lumbar dorsal spinal cord for immunoprecipitation with pSer, BRAF, or GluN1 antibodies. The immunoprecipitated proteins and input proteins were used for immunoblotting analysis. β-actin and PSD95 were used as the loading control. Data are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Statistical significance was determined by 2-tailed Student’s t test for B and by 1-way ANOVA followed by Tukey’s post hoc test for A and C.

Morphine treatment increases synaptic trafficking of BRAF-NMDAR complexes in the spinal cord. Treatment with morphine enhances the physical association of ERK1/2 with NMDARs in the spinal cord (18). We used coimmunoprecipitation to determine whether BRAF is physically associated with NMDARs and MORs in the spinal cord from rats treated with saline or morphine for 7 days. Synaptosomal proteins extracted from rat spinal cord tissues were immunoprecipitated with a BRAF antibody followed by immunoblotting for GluN1. GluN1 was detected in the precipitates obtained using a BRAF antibody (Figure 4B). The abundance of BRAF-GluN1 protein complexes, as well as the total protein amount of BRAF and GluN1 in spinal cord synaptosomes (the input), were substantially higher in morphine-treated rats than in saline-treated rats (Figure 4B). However, GluN1 was not present in the BRAF immunoprecipitates in the DRG tissue from rats treated with saline or morphine (Supplemental Figure 2). Furthermore, MOR was not detected in BRAF immunoprecipitates from either the spinal cord (Figure 4B) or DRG (Supplemental Figure 2) of rats treated with saline or morphine, indicating that BRAF does not directly interact with MORs in these tissues. These data suggest that opioid treatment promotes BRAF-NMDAR interactions and their trafficking at spinal cord synapses.

Additionally, coimmunoprecipitation analysis revealed that the GluN1 antibody, but not the control IgG, precipitated both BRAF and ERK1/2 from lumbar spinal cord tissues of 2 human donors (Supplemental Figure 3). Notably, the amount of BRAF protein coprecipitated by GluN1 appeared to be greater in the donor who died of methadone intoxication than in the donor who died of generalized dystonia (Supplemental Figure 3), suggesting that opioids may also enhance the association between BRAF and NMDARs in the human spinal cord.

Morphine treatment promotes synaptic trafficking of α2δ-1–bound NMDARs in the spinal cord through BRAF. α2δ-1 is a recently identified interacting protein of NMDARs and AMPARs (43–45). It preferentially binds to phosphorylated NMDARs, facilitating their synaptic trafficking in conditions such as neuropathic pain and opioid-induced hyperalgesia (16, 45–48). To determine whether BRAF activity contributes to morphine-induced synaptic expression of α2δ-1–bound NMDARs, we analyzed synaptosomal proteins from the dorsal spinal cord of rats treated for 7 days with saline, morphine + vehicle, or morphine + vemurafenib. Immunoblots revealed that morphine treatment increased GluN1 and α2δ-1 levels in spinal cord synaptosomes compared with saline controls, and these increases were largely normalized by vemurafenib cotreatment (Figure 4C). Furthermore, in the GluN1 immunoprecipitates, morphine treatment substantially elevated α2δ-1 levels, indicating enhanced α2δ-1–NMDAR interactions. Cotreatment with vemurafenib largely diminished this morphine-induced increase in α2δ-1–NMDAR complexes (Figure 4C). These findings suggest that BRAF activity plays a critical role in opioid-induced synaptic trafficking of α2δ-1–bound NMDARs in the spinal cord.

BRAF mediates morphine-induced hyperactivity of NMDARs at primary afferent terminals in the spinal cord. Hyperactivity of presynaptic NMDARs in the spinal dorsal horn is a critical mechanism underlying opioid-induced hyperalgesia and tolerance (3, 12, 15). To assess whether BRAF activity contributes to this process, we performed electrophysiological recordings in lamina II neurons from spinal cord slices of rats treated with saline or morphine for 7 days. The baseline frequency — but not amplitude — of miniature excitatory postsynaptic currents (mEPSCs) was notably higher in morphine-treated rats than in saline controls (Figure 5). Bath application of 50 μM 2-amino-5-phosphonopentanoic acid (AP5), a specific NMDAR antagonist, for 6 minutes rapidly decreased the frequency of mEPSCs in spinal cord slices from morphine-treated rats but had no such effect on saline-treated rats. Treatment of spinal cord slices with 5 μM vemurafenib for 30 minutes reversed the elevated baseline frequency of mEPSCs from morphine-treated rats (Figure 5). In these spinal cord slices treated with vemurafenib, AP5 application had no further effect on the mEPSCs.

Morphine treatment increases NMDAR-dependent frequency of mEPSCs in spinalFigure 5

Morphine treatment increases NMDAR-dependent frequency of mEPSCs in spinal dorsal horn neurons through BRAF. (A–D) Representative recording traces (A), cumulative plots (B), and summary data (C and D) show the effect of bath application of 50 μM AP5 on the frequency and amplitude of mEPSCs in lamina II neurons from rats treated with saline or morphine (5 mg/kg) twice daily for 7 days. Spinal cord slices were treated with vemurafenib (VEM, 5 μM) or vehicle (Veh) for 30 minutes immediately before recording. Recordings of mEPSCs were obtained from 5 rats per group (n = 14 neurons for saline + Veh group, n = 15 neurons for Mor + Veh group, n = 14 neurons for Mor + VEM group). Data are shown as means ± SEM. **P < 0.01, ***P < 0.001 (2-way ANOVA followed by Tukey’s post hoc test).

We next determined the effect of vemurafenib on EPSCs in spinal lamina II neurons monosynaptically evoked from the dorsal root stimulation. The baseline amplitude of evoked EPSCs was greater in morphine-treated rats than in saline-treated rats. Bath application of AP5 readily decreased the amplitude of evoked EPSCs in morphine-treated rats but had no effect in saline-treated rats (Figure 6). Treatment of spinal cord slices with vemurafenib normalized the elevated baseline amplitude of evoked EPSCs in morphine-treated rats to a level similar to that in saline-treated rats (Figure 6). In spinal cord slices pretreated with vemurafenib, subsequent application of AP5 had no further effect on the amplitude of evoked EPSCs.

Morphine treatment enhances the amplitude of dorsal root–evoked EPSCs and pFigure 6

Morphine treatment enhances the amplitude of dorsal root–evoked EPSCs and paired-pulse ratio of EPSCs in the spinal cord through BRAF. (A–D) Representative recording traces (A and B) and summary data (C and D) show the effect of bath application of 50 μM AP5 on the amplitude of dorsal root–evoked EPSCs and paired-pulse ratio (PPR) in lamina II neurons from rats treated with saline or morphine (5 mg/kg) twice daily for 7 days. Spinal cord slices were treated with vemurafenib (VEM, 5 μM) or vehicle (Veh) for 30 minutes immediately before recording. Monosynaptic EPSCs were elicited by electrical stimulation of the dorsal root. Recordings of evoked EPSCs (n = 16 neurons for saline + Veh group, n = 15 neurons for Mor + Veh group, n = 13 neurons for Mor + VEM group) and the PPR (n = 14 neurons for saline + Veh group, n = 17 neurons for Mor + Veh group, n = 13 neurons for Mor + VEM) were obtained from 5 rats per group. Data are shown as mean ± SEM. ***P < 0.001 (2-way ANOVA followed by Tukey’s post hoc test).

We also examined the paired-pulse ratio (PPR) of EPSCs in spinal lamina II neurons monosynaptically evoked from dorsal root stimulation, which reflects the probability of glutamate release from presynaptic terminals based on responses to paired stimuli (15, 16). The baseline PPR was notably lower in morphine-treated rats than in saline-treated rats. Bath application of AP5 preferentially reduced the first evoked EPSCs more than the second, resulting in an increased PPR in morphine-treated rats (Figure 6). However, AP5 had no effect on the PPR in saline-treated rats. Pretreatment with vemurafenib restored the reduced baseline PPR in morphine-treated rats (Figure 6), and subsequent AP5 application produced no additional effect. Together, these results suggest that increased BRAF activity mediates opioid-induced presynaptic NMDAR hyperactivity at primary afferent terminals in the spinal dorsal horn.

Inhibition of BRAF or MEK reduces morphine-induced hyperalgesia and tolerance. To determine whether BRAF activity contributes to morphine-induced hyperalgesia and tolerance, adult rats were treated with morphine (5 mg/kg, i.p., twice daily) for 7 consecutive days. Vemurafenib (10 mg/kg, i.p.) or vehicle was administered 15 minutes prior to each morphine injection. Withdrawal threshold and latency in response to noxious pressure and radiant heat stimuli were measured 30 minutes before (baseline) and 30 minutes after the first daily morphine injection. Daily morphine administration in vehicle-treated rats produced a gradual reduction in baseline withdrawal threshold and latency, indicating mechanical and thermal hyperalgesia (Figure 7A). These rats also exhibited a progressive decline in the analgesic effect of morphine, reflecting the development of analgesic tolerance (Figure 7A). Cotreatment with vemurafenib substantially attenuated both the reduction in baseline withdrawal threshold and latency and the loss in morphine analgesic efficacy (Figure 7A).

Inhibition of BRAF or MEK activity or BRAF knockdown reduces morphine-inducFigure 7

Inhibition of BRAF or MEK activity or BRAF knockdown reduces morphine-induced hyperalgesia and tolerance. (A and B) Time course of the effect of vemurafenib (VEM, A) or selumetinib (SEL, B) on morphine-induced hyperalgesia and tolerance. Rats were intraperitoneally injected with morphine (Mor, 5 mg/kg) twice daily for 7 days. VEM (10 mg/kg) or SEL (10 mg/kg) was intraperitoneally injected 15 minutes prior to each morphine injection daily. Nociceptive threshold and latency were tested before (baseline) and 30 minutes after the first morphine injection daily. (C and D) Time course of the acute analgesic effect of morphine in rats cotreated with VEM (C) or SEL (D). Nociceptive threshold and latency were tested after the first morphine injection on day 1 and day 7. (E) Flowchart diagram shows the timeline of injection of siRNA (3 μg, intrathecally, once daily) and morphine (5 mg/kg, i.p., twice daily) used for behavioral testing. Braf-specific siRNA or control siRNA were injected 15 minutes prior to the first morphine injection daily. (F) Time course of morphine-induced hyperalgesia and tolerance in rats treated with Braf-specific siRNA or control (Cont) siRNA (n = 9 rats per group). Pressure withdrawal threshold and thermal withdrawal latency were measured before (baseline) and 30 minutes after the first morphine (Mor) injection daily on days 1–7. (G) Time course of the acute analgesic effect produced by the first morphine injection on day 1 and day 7 in rats treated with Braf-specific siRNA or control (Cont) siRNA (n = 9 rats per group). *P < 0.05, **P < 0.01, ***P < 0.001 versus respective values at day 1 or time (min) 0; #P < 0.05, ##P < 0.01, ###P < 0.001 versus respective control groups at the same time point (2-way ANOVA followed by Tukey’s post hoc test).

To determine whether MEK activity, which is downstream of BRAF, also mediates morphine-induced hyperalgesia and tolerance, we administered selumetinib (10 mg/kg, i.p.), a clinically available MEK1/2 inhibitor (49), 15 minutes prior to morphine (5 mg/kg, i.p.) twice daily for 7 days. Similar to vemurafenib, selumetinib markedly attenuated reductions in baseline withdrawal threshold and latency and preserved morphine’s analgesic effect (Figure 7B).

Furthermore, we examined the time course of the acute analgesic response to morphine on the first and seventh treatment days. In the vehicle group, morphine (5 mg/kg, i.p.) produced a transient analgesic effect on both days, reflected by increased pressure withdrawal threshold and thermal withdrawal latency, lasting for 90–120 minutes after injection (Figure 7C). Notably, cotreatment with vemurafenib potentiated these morphine-induced increases in withdrawal threshold and latency on both days (Figure 7C). Similarly, cotreatment with selumetinib potentiated morphine-induced increases on both days (Figure 7D). These findings suggest that the increased BRAF activity, along with its downstream MEK signaling, counteracts opioid analgesia and contributes to the development of opioid-induced hyperalgesia and tolerance.

siRNA-mediated BRAF knockdown at the spinal cord level attenuates morphine-induced hyperalgesia and tolerance. To determine whether spinal BRAF contributes to opioid-induced hyperalgesia and tolerance, we intrathecally injected 3 μg of Braf-specific siRNA or control siRNA in rats once daily for 7 days and then collected the lumbar DRG and dorsal spinal cord tissue to confirm the knockdown efficacy. Intrathecally injected siRNA knocks down the target in both the DRG and spinal cord tissues (50, 51). As expected, compared with the control siRNA, Braf-specific siRNA markedly decreased BRAF protein levels in both the DRG and spinal cord tissues (Supplemental Figure 4).

Next, we intrathecally injected Braf-specific siRNA or control siRNA in rats for 2 days followed by concurrent treatment with morphine (5 mg/kg, i.p., twice daily) for 7 days (Figure 7E). Compared with control siRNA, Braf-specific siRNA mitigated morphine-induced reductions in baseline pressure withdrawal threshold and thermal withdrawal latency and attenuated the decline in the analgesic effect of morphine (Figure 7F). Furthermore, Braf-specific siRNA potentiated morphine-induced increases in withdrawal threshold and latency on both days 1 and 7 (Figure 7G). These findings suggest that BRAF at the spinal cord level mediates opioid-induced hyperalgesia and tolerance and opposes opioid analgesia.

Conditional Braf knockout in DRG neurons attenuates morphine-induced hyperalgesia and tolerance. MORs and NMDARs expressed in DRG neurons play critical roles in opioid-induced hyperalgesia and tolerance (11, 12). We therefore investigated whether BRAF in DRG neurons is required for these processes. To this end, we crossed BrafFl+/+ (52) and AviliCre/ERT2+ (53) mice to generate BrafFl+/+:AviliCre/ERT2+ mice and administered tamoxifen to induce conditional Braf knockout (Braf-cKO) in DRG neurons. As expected, Braf-cKO mice exhibited near complete loss of BRAF expression in the DRG (Figure 8A). BRAF protein levels in spinal cord tissues and spinal cord synaptosomal fractions were also markedly lower in Braf-cKO mice than in WT mice. In WT mice, morphine treatment increased BRAF expression in spinal cord synaptosomes. However, morphine failed to increase BRAF levels in spinal cord synaptosomes in Braf-cKO mice (Figure 8A).

Braf knockout in primary sensory neurons attenuates morphine-induced BRAF tFigure 8

Braf knockout in primary sensory neurons attenuates morphine-induced BRAF translocation as well as hyperalgesia and tolerance. (A) Representative immunoblot images and quantification show BRAF protein expression in the DRG and spinal cord (SC) of conditional Braf knockout (cKO) and WT mice treated with saline (Sal) or morphine (Mor, 10 mg/kg, twice daily) for 7 days (n = 6 mice per group). Total and synaptosomal (Syn) proteins were extracted from lumbar DRG and dorsal spinal cord tissues for immunoblotting. GAPDH or PSD95 was used as a loading control. (B) Representative immunoblot images and quantification show the amount of pMEK and total MEK in the spinal cord from WT and Braf-cKO mice treated with saline or morphine (10 mg/kg, i.p., twice daily) for 7 consecutive days (n = 6 mice per group). Total and synaptosomal (Syn) proteins from the dorsal spinal cord were extracted for immunoblotting. (C) Time course of hyperalgesia and tolerance in WT (n = 11 mice) and Braf-cKO (n = 13 mice) treated with morphine (10 mg/kg, twice daily) for 7 days. Pressure withdrawal threshold and heat withdrawal latency were measured before (baseline) and 30 minutes after the first morphine (Mor) injection daily. (D) Time course of the acute analgesic effect produced by the first morphine injection on day 1 and day 7 in WT (n = 11 mice) and Braf-cKO (n = 13 mice). Data are expressed as means± SEM. In Panels A and B, **P < 0.01, ***P < 0.001 (1-way ANOVA followed by Tukey’s post hoc test). In C and D, *P < 0.05, **P < 0.01, ***P < 0.001 versus respective values at day 1 or time (min) 0. #P < 0.05, ###P < 0.001 versus respective WT groups at the same time point (2-way ANOVA followed by Tukey’s post hoc test).

We next determined whether BRAF in DRG neurons contributes to morphine-induced BRAF overactivity in the spinal cord. Braf-cKO and WT mice were treated with saline or morphine (10 mg/kg, i.p., twice daily for 7 days), and total and synaptosomal proteins were extracted from lumbar dorsal spinal cords. The total and synaptosomal MEK1/2 protein levels were similar between WT and Braf-cKO mice treated with saline. In WT mice, morphine treatment increased pMEK1/2 levels in both total lysates and synaptosomal fractions (Figure 8B), consistent with data from rats. This morphine-induced increase was diminished in Braf-cKO mice (Figure 8B), indicating that BRAF from DRG neurons drives the morphine-induced BRAF overactivity in the spinal cord.

We then determined whether BRAF in DRG neurons mediates morphine-induced hyperalgesia and tolerance. Braf-cKO and WT mice were treated with morphine (10 mg/kg, twice daily) for 7 days, and hindpaw withdrawal threshold and latency were measured before (baseline) and 30 minutes after the first daily morphine injection. Acute analgesic effect of the first morphine injection was also assessed on days 1 and 7. Baseline mechanical and thermal thresholds were comparable between Braf-cKO and WT mice prior to morphine treatment (Figure 8C). In WT mice, morphine treatment produced progressive reductions in baseline withdrawal thresholds and analgesic efficacy, indicative of hyperalgesia and tolerance. These reductions were attenuated in Braf-cKO mice (Figure 8C).

Furthermore, morphine injection transiently increased pressure withdrawal threshold and heat withdrawal latency on both days 1 and 7 in both genotypes (Figure 8D). Notably, acute analgesic effects of morphine were greater in Braf-cKO mice than in WT mice on both days (Figure 8D). These results suggest that BRAF originating from DRG neurons promotes opioid-induced hyperalgesia and tolerance and antagonizes opioid analgesia.

BRAF from DRG neurons mediates morphine-induced NMDAR phosphorylation and synaptic trafficking of α2δ-1–bound NMDARs in the spinal cord. We next investigated whether BRAF from DRG neurons contributes to morphine-induced NMDAR phosphorylation and synaptic expression in the spinal cord. Braf-cKO and WT mice were treated with morphine (10 mg/kg, twice daily) for 7 days. Synaptosomal proteins were extracted from lumbar dorsal spinal cords and subjected to immunoprecipitation using a pSer antibody. Both total synaptosomal proteins (input) and pSer-precipitated proteins were analyzed by immunoblotting with a GluN1 antibody. Morphine treatment increased GluN1 levels in both input and pSer precipitates in WT mice compared with saline-treated WT mice (Figure 9A). In contrast, morphine treatment failed to increase GluN1 levels in either input or pSer precipitates in Braf-cKO mice (Figure 9A). These data suggest that BRAF expressed in DRG neurons is essential for opioid-induced enhancement of NMDAR phosphorylation and synaptic trafficking in the spinal cord.

Braf knockout in primary sensory neurons blocks morphine-induced NMDAR phosFigure 9

Braf knockout in primary sensory neurons blocks morphine-induced NMDAR phosphorylation and synaptic trafficking of α2δ-1–bound NMDARs in the spinal cord. (A) Representative immunoblot images and quantification show the amount of total GluN1 and phosphorylated GluN1 from spinal cord synaptosomes of WT mice treated with saline (Sal) or morphine (Mor) as well as Braf-cKO mice treated with morphine (n = 6 mice per group). (B) Representative immunoblot images and quantification show the amount of α2δ-1, GluN1, and α2δ-1–GluN1 complexes in spinal cord synaptosomes from WT mice treated with saline (Sal) or morphine (Mor) as well as Braf-cKO mice treated with morphine (n = 6 mice per group). Synaptosomal proteins from the dorsal spinal cord were immunoprecipitated (IP) with a pSer or GluN1 antibody. Both input and precipitated proteins were then immunoblotted for α2δ-1 and GluN1. PSD95 was used as a loading control. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (1-way ANOVA followed by Tukey’s post hoc test).

Given that Braf-cKO in DRG neurons attenuated morphine-induced NMDAR phosphorylation and synaptic trafficking in the spinal cord, we investigated whether DRG neuron–derived BRAF contributes to morphine-induced synaptic expression of α2δ-1–bound NMDARs in the spinal cord. Synaptosomal proteins were extracted from dorsal spinal cord tissues of Braf-cKO and WT mice treated with morphine for 7 days. Total synaptosomal proteins (input) and GluN1-immunoprecipitated proteins were analyzed by immunoblotting with GluN1 and α2δ-1 antibodies. Consistent with rat data, morphine markedly increased total α2δ-1 levels in synaptosomal input from WT mice. In WT mice, morphine also substantially increased α2δ-1 levels in GluN1 immunoprecipitates (Figure 9B). Remarkably, morphine-induced increases in α2δ-1 amount and α2δ-1–GluN1 complexes in spinal cord synaptosomes were diminished in Braf-cKO mice (Figure 9B). These findings suggest that opioids potentiate synaptic expression of α2δ-1–bound NMDARs in the spinal cord through BRAF signaling in DRG neurons.

Conditional Braf knockout in DRG neurons diminishes morphine-induced presynaptic NMDAR hyperactivity in the spinal dorsal horn. Finally, we determined the role of BRAF from DRG neurons in morphine-induced hyperactivity of presynaptic NMDARs in spinal dorsal horn neurons. Braf-cKO and WT mice were treated with morphine for 7 days, and lumbar spinal cord slices were used for electrophysiological recordings. The baseline frequency, but not amplitude, of mEPSCs in lamina II neurons was substantially higher in morphine-treated WT mice than in saline-treated WT mice (Figure 10). The morphine-induced increase in mEPSCs frequency in WT mice was rapidly reduced by bath application of AP5. In Braf-cKO mice, however, morphine treatment did not increase baseline mEPSC frequency, and subsequent AP5 application had no effect (Figure 10).

BRAF in primary sensory neurons underlies the morphine-induced increase inFigure 10

BRAF in primary sensory neurons underlies the morphine-induced increase in the frequency of NMDAR-dependent mEPSCs in spinal dorsal horn neurons. (A–D) Representative recording traces (A), cumulative plots (B), and summary data (C and D) show the effect of bath application of 50 μM AP5 on the frequency and amplitude of mEPSCs in lamina II neurons from WT and conditional Braf knockout (cKO) mice treated with saline or morphine (Mor, 10 mg/kg twice daily) for 7 days. Recordings of mEPSCs were obtained from 5 mice per group (n = 16 neurons for WT + saline group, n = 15 neurons for WT + Mor group, n = 14 neurons for cKO + Mor group). Data presented are means ± SEM. ***P < 0.001, 2-way ANOVA followed by Tukey’s post hoc test.

In WT mice, morphine treatment also increased the baseline amplitude of EPSCs in lamina II neurons monosynaptically evoked by dorsal root stimulation compared with saline-treated WT mice (Figure 11). In contrast, morphine treatment did not affect the baseline amplitude of evoked EPSCs in lamina II neurons of Braf-cKO mice. Bath application of AP5 rapidly decreased the amplitude of evoked EPSCs in morphine-treated WT mice but had no effect in saline-treated WT mice or morphine-treated Braf-cKO mice (Figure 11).

Braf knockout in primary sensory neurons eliminates morphine-induced changeFigure 11

Braf knockout in primary sensory neurons eliminates morphine-induced changes in the amplitude of dorsal root–evoked EPSCs and paired-pulse ratio of EPSCs in spinal dorsal horn neurons. (A–D) Representative current traces (A and B) and quantification (C and D) show the effect of bath application of 50 μM AP5 on the amplitude of dorsal root–evoked EPSCs and paired-pulse ratio (PPR) of EPSCs in lamina II neurons from WT and conditional Braf knockout (cKO) mice treated with saline or morphine (Mor, 10 mg/kg twice daily) for 7 days. Recordings of evoked EPSCs (n = 13 neurons for WT + saline group, n = 16 neurons for WT + morphine group, n = 15 neurons for cKO + morphine group) and the PPR (n = 15 neurons for WT + saline group, n = 16 neurons for WT + morphine group, n = 15 neurons for cKO + morphine group) were obtained from 5 mice per group. Data presented are means ± SEM. ***P < 0.001; 2-way ANOVA followed by Tukey’s post hoc test.

In addition, morphine treatment decreased baseline PPR of evoked EPSCs in WT mice compared with saline-treated WT mice. Bath application of AP5 increased the PPR of evoked EPSCs in morphine-treated WT mice but had no such effect in saline-treated WT mice (Figure 11). In Braf-cKO mice, morphine treatment did not alter baseline PPR, which remained comparable with saline-treated WT mice (Figure 11). Subsequent AP5 application had no observable effect on baseline PPR in Braf-cKO mice. Collectively, these results suggest that BRAF from DRG neurons is required for opioid-induced hyperactivity of NMDARs at primary afferent terminals in the spinal dorsal horn.

Discussion

A major finding of our study is that opioid treatment activates the MEK/ERK signaling pathway by enhancing BRAF activity in the spinal cord. As a core component of the RAS/RAF/MEK/ERK cascade, RAF primarily functions by phosphorylating and activating MEK (54), which, in turn, activates ERK. Activated ERK subsequently phosphorylates a wide range of downstream targets involved in diverse cellular processes. In CHO, COS-7, and HEK293 cell lines transfected with MORs, opioids activate ERK1/2 through Gαi/o-coupled G-proteins and their Gβγ subunits (21–26). ERK inhibition attenuates opioid-induced hyperalgesia and tolerance (18, 55). In this study, we demonstrated that morphine administration markedly increased phosphorylation of both MEK and ERK in the spinal cord, but not in the DRG. This morphine-induced BRAF kinase overactivity was further supported by direct measurements of BRAF-mediated MEK1 phosphorylation in the spinal cord. Although vemurafenib is widely recognized as a selective inhibitor of BRAFV600E, it also potently inhibits WT BRAF (40, 56, 57). We found that vemurafenib did not affect basal BRAF activity in the spinal cord of vehicle-treated rats but effectively reversed morphine-induced BRAF activation, confirming its efficacy in suppressing overactive WT BRAF in neural tissues. Furthermore, morphine-induced MEK phosphorylation was abolished in mice with conditional Braf knockout in DRG neurons, providing strong evidence that opioid treatment enhances BRAF activity at primary afferent terminals in the spinal cord, thereby driving downstream MEK/ERK signaling.

A striking finding of our study is that opioid treatment promotes BRAF translocation from DRG neurons to the spinal cord without altering Braf mRNA levels in either location. Morphine treatment reduced BRAF protein levels in the DRG while increasing its abundance in spinal cord synaptosomes. In contrast, morphine treatment did not alter total MEK or ERK levels in either the DRG or spinal cord. Conditional Braf knockout in DRG neurons not only eliminated BRAF expression in the DRG but also diminished BRAF levels in spinal cord synaptosomes. These findings suggest that a substantial fraction of spinal BRAF originates from DRG neuronal somata and is recruited to their central terminals upon opioid exposure. In support of this interpretation, morphine-induced BRAF recruitment to spinal synaptosomes was abolished by Braf ablation in DRG neurons. Such trafficking may be essential for precise spatiotemporal regulation of downstream signaling, particularly MEK/ERK phosphorylation at nociceptor terminals in the spinal dorsal horn. Morphine treatment selectively promotes the translocation of BRAF from DRG neuronal somata to their central terminals, explaining why increased BRAF protein was readily detected in spinal synaptosomes — enriched in primary afferent terminals — but not in whole dorsal spinal tissues. Notably, morphine or fentanyl treatment similarly enhances the anterograde trafficking of Gαq-coupled mGluR5 and α2δ-1 from DRG neurons to their central terminals (16, 19). Together, these findings suggest that the mGluR5-Gαq-PKC and BRAF-MEK-ERK signaling pathways may operate collaboratively within a large protein complex in primary sensory neurons through which opioids modulate spinal synaptic plasticity.

The mechanisms by which opioid treatment promotes BRAF trafficking from the DRG to the spinal cord remain unclear. We found that blocking MORs with FNA eliminated morphine-induced BRAF trafficking to the spinal cord, indicating a critical role for MOR activation. However, we did not detect a direct interaction between MOR and BRAF in either the DRG or spinal cord. Opioid treatment increases PLC and PKC activity in DRG neurons (58), potentially leading to BRAF phosphorylation and subsequent trafficking from DRG neurons to spinal synapses. Motor proteins, such as dyneins and kinesins (59), may also contribute to opioid-induced BRAF transport from the DRG to the spinal cord. While RAF proteins typically activate ERK signaling as homo- and heterodimers in the presence of active RAS (60, 61), activated BRAF appears as monomers in SDS-PAGE gels (62). We detected only BRAF monomers (approximately 85 kDa) in the DRG and spinal cord from both control and morphine-treated rats. Because BRAF dimers are stabilized by salt bridges and hydrogen bonds (63), they may dissociate under denaturing SDS-PAGE conditions.

Our findings reveal that BRAF derived from primary sensory neurons is essential for opioid-induced NMDAR phosphorylation in the spinal cord. Both pharmacological BRAF inhibition and Braf knockout in DRG neurons abolished morphine-induced NMDAR phosphorylation in spinal cord synaptosomes, indicating that BRAF activity at primary afferent central terminals is required for this process. Furthermore, BRAF directly interacted with GluN1 in the spinal cord, and this interaction was augmented by morphine treatment. In contrast, BRAF did not associate with GluN1 or MORs in the DRG. Because morphine also promotes ERK association with NMDARs in the spinal cord (18), these findings suggest a direct role of BRAF-ERK signaling in opioid-induced NMDAR phosphorylation. We demonstrated that GluN1 formed protein complexes with BRAF and ERK in human spinal cord tissues, indicating that coupling of NMDARs to the BRAF-ERK pathway is conserved across species. Notably, the GluN1-BRAF complex appeared more abundant in tissue from an opioid overdose donor than from a donor without documented opioid use. Although the central terminals of DRG neurons reside in the spinal dorsal horn, they remain integral components of DRG neurons. Our findings collectively suggest that BRAF physically associates with NMDARs and promotes NMDAR phosphorylation through activated downstream signaling at primary afferent central terminals, underscoring the spatial specificity of BRAF signaling in opioid-induced NMDAR phosphorylation.

Although BRAF was required for morphine-induced GluN1 phosphorylation and physically interacted with GluN1, it remains unresolved whether BRAF directly phosphorylates NMDARs. ERK preferentially phosphorylates serine or threonine residues within serine/threonine-proline (S/TP) motifs (64). While the GluN1 C-terminal tail lacks canonical S/TP motifs, an SP motif (S584-P585) is present within its first cytoplasmic domain, suggesting the possibility of direct ERK-mediated phosphorylation. Opioids also increase PKC activity in the spinal cord (1, 3, 12, 65), and PKC-dependent NMDAR phosphorylation contributes to opioid-induced synaptic trafficking and receptor hyperactivity (3, 12). PKC further links Gαq-coupled mGluR5 signaling to opioid-induced NMDAR hyperactivity in the spinal dorsal horn (20). Although PKC is required for opioid-induced ERK activation in cell lines (23, 66), the precise convergence of the Gαq–PKC and BRAF-MEK-ERK pathways in regulating NMDAR phosphorylation remains to be determined. Because Gαi and Gαq proteins can cooperatively activate ERK (33), and mGluR5, BRAF, and ERK each associate directly with NMDARs (18, 19, 67), it is plausible that opioid-induced BRAF/MEK/ERK signaling phosphorylates NMDARs either directly or indirectly through the Gαq-PKC pathway.

Another notable finding is that BRAF activity is critically involved in opioid-induced synaptic expression of α2δ-1–bound NMDARs in the spinal cord. α2δ-1, originally characterized as a calcium channel subunit, is now recognized as a phospho-binding protein that preferentially interacts with phosphorylated NMDARs (45, 46, 68). Morphine treatment enhances the α2δ-1–NMDAR interaction and synaptic localization of α2δ-1–bound NMDARs at primary afferent central terminals (16). Inhibition of α2δ-1 with gabapentinoids or disruption of the α2δ-1–NMDAR complex suppresses opioid-induced presynaptic NMDAR hyperactivity, hyperalgesia, and tolerance (16). In this study, both pharmacological BRAF inhibition and conditional Braf ablation in DRG neurons reversed morphine-induced increases in synaptic expression of α2δ-1–bound NMDARs, supporting BRAF as an upstream regulator of opioid-induced synaptic trafficking of NMDARs in the spinal dorsal horn. Although our study focused on NMDAR-related mechanisms, opioid-induced BRAF activity may also affect other substrates, including MORs and associated G proteins, thereby contributing to reduced opioid analgesic efficacy.

Our study provides compelling evidence that BRAF signaling is a key driver of opioid-induced NMDAR presynaptic hyperactivity in the spinal dorsal horn. NMDAR hyperactivity at primary afferent central terminals mediates opioid-induced hyperalgesia and tolerance (12, 16, 18–20). Increased phosphorylation and synaptic trafficking of α2δ-1–bound NMDARs underlie presynaptic NMDAR hyperactivity in this region (16, 20). We have shown that ERK inhibition blocks opioid-induced presynaptic NMDAR hyperactivity (18). Using a spinal cord slice preparation that preserves native MORs and the synaptic connection between primary afferents and spinal dorsal horn neurons, we found that inhibiting BRAF with vemurafenib or ablating Braf in DRG neurons diminished morphine-induced, NMDAR-mediated increases in mEPSC frequency evoked EPSC amplitude, with corresponding changes in EPSC paired-pulse ratio. These results establish BRAF overactivity as a critical upstream driver of opioid-induced presynaptic NMDAR hyperactivity in the spinal cord and underscore the role of BRAF signaling in primary sensory neurons in shaping opioid-induced nociceptive transmission.

Our findings indicate that BRAF in primary sensory neurons is a key mediator of opioid-induced hyperalgesia and tolerance. Opioid-induced presynaptic NMDAR hyperactivity enhances nociceptive input from TRPV1-expressing primary afferents to spinal excitatory neurons, resulting in hyperalgesia (2, 12, 15, 69). Because MOR agonists do not inhibit NMDAR-mediated nociceptive transmission (16, 19, 20), this hyperactivity also contributes to reduced opioid analgesic efficacy and tolerance. We previously showed that spinal MAPK/ERK inhibition attenuates morphine-induced hyperalgesia and tolerance (18). Here, BRAF inhibition with vemurafenib or MEK inhibition with selumetinib produced similar effects, with greater efficacy against hyperalgesia than tolerance. In addition, siRNA-induced Braf knockdown or conditional Braf ablation in DRG neurons enhanced acute morphine analgesia and attenuated both hyperalgesia and tolerance. Notably, morphine produced greater analgesic efficacy on day 1 in Braf-cKO mice and Braf-specific siRNA–treated rats than in controls, suggesting that BRAF contributes to the initiation of opioid-induced maladaptive plasticity. These complementary loss-of-function analyses provide strong evidence that BRAF signaling in primary sensory neurons counteracts opioid analgesia and promotes hyperalgesia and tolerance.

In conclusion, our study identifies aberrant BRAF signaling as a key driver of opioid-induced hyperalgesia and tolerance by promoting NMDAR phosphorylation and hyperactivity at nociceptor central terminals in the spinal cord (Supplemental Figure 5). These findings reinforce the concept that signaling events at primary afferent central terminals are critical determinants of opioid analgesic efficacy and adverse plasticity (11, 12, 15, 18–20, 70). Although NMDAR antagonists can alleviate opioid-induced hyperalgesia and tolerance in both preclinical and clinical settings (1, 3, 5, 7), their clinical utility is limited by severe adverse effects. Our findings raise the possibility that BRAF inhibitors, currently used in cancer therapy, may represent an alternative strategy to reduce opioid-induced hyperalgesia and tolerance. Another implication of our study is the potential for opioids to promote tumor growth. Constitutively active BRAF mutants, such as BRAFV600E, an oncogenic gain-of-function mutation, drive cancer progression through growth-promoting signaling (36, 37). Although MORs are normally restricted to neurons, they are also expressed in certain cancers, including neuroblastoma (71, 72), and morphine can stimulate the growth of human glioblastoma cells (73). These observations suggest that opioid-induced BRAF activation may inadvertently promote the growth of MOR-expressing cancer cells. Therefore, concurrent use of BRAF inhibitors may not only enhance opioid analgesic efficacy but also potentially mitigate the risk of opioid-associated tumor progression.

Methods

Sex as a biological variable. Sex was not considered as a biological variable because no differences were observed in opioid-induced hyperalgesia and tolerance or agent treatment effects between male and female animals in this study.

Animal models. Detailed procedures for animal models and drug administration are provided in the Supplemental Methods.

Nociceptive behavioral tests. The pressure withdrawal threshold was measured using a digital Randall-Selitto paw pressure device (#2500, IITC Life Science). The device applied steadily increasing force to the midplantar glabrous surface of the animal’s hindpaw via a pointed end. The force was immediately stopped upon a withdrawal response, and the threshold was recorded (74, 75). The thermal withdrawal latency was measured using a thermal testing apparatus (#390G, IITC Life Science). Animals were placed on a glass surface maintained at 30°C for acclimation. A mobile radiant heat stimulus was applied to the plantar surface of the hindpaw until the animal lifted or licked the hindpaw (2, 69). The time taken for hindpaw withdrawal was recorded as the thermal withdrawal latency.

Immunoprecipitation and immunoblotting. Detailed procedures for synaptosome preparation, immunoprecipitation, and immunoblotting are provided in the Supplemental Methods. The specificity of MOR, GluN1, and α2δ-1 antibodies has been validated using knockout mice (11, 16, 19, 20, 48, 76).

BRAF kinase activity measurement. BRAF activity in the spinal cord was assessed by measuring phosphorylation of recombinant MEK1 as previously reported (54). Briefly, spinal cord tissues were lysed in IP lysis buffer (#87788, Thermo Fisher Scientific) and were cleared by centrifugation at 10,000 × g for 10 minutes at 4°C. Five μg of BRAF antibody (#77622, Cell Signaling Technology) and 100 μL protein G agarose beads (#16-266, MilliporeSigma) were added to the lysates and incubated overnight at 4°C on a slow rotator. The BRAF immunocomplex was washed three times in ice-cold IP lysis buffer to remove unbound material. The immunocomplex was then suspended in ice-cold reaction buffer containing 20 mM Tris (pH 7.4), 20 mM NaCl, 1 mM DTT, 10 mM MgCl2, and 1 mM MnCl2. The kinase reaction was initiated in the presence of 20 mM ATP and 500 ng of recombinant polyhistidine-tagged MEK1 substrate (#sc-4025, Santa Cruz Biotechnology) incubating at 30°C for 30 minutes with gentle agitation. The reaction was terminated by adding loading buffer containing 1% SDS and 100 mM DTT, followed by boiling for 5 minutes. The eluted samples were then used for immunoblotting analysis of phospho-MEK.

PCR and immunofluorescence labeling. Detailed procedures for quantitative PCR and immunofluorescence labeling are provided in the Supplemental Methods.

Electrophysiological recordings in spinal cord slices. Detailed procedures for spinal cord slice preparation and recordings are described in the Supplemental Methods. EPSCs from lamina II neurons were recorded in whole-cell voltage-clamp mode at a holding potential of –60 mV, as we described previously (12, 77). EPSCs were evoked by electrical stimulation (0.6 mA, 0.5 ms, and 0.1 Hz) of the dorsal root to elicit glutamate release from primary afferent fibers. Monosynaptic EPSCs were identified by constant latency and absence of conduction failure during 20 Hz stimulation (15, 47). Paired-pulse ratio (PPR) of evoked EPSCs was determined by delivering a pair of stimuli at 50-ms intervals. PPR was calculated as the ratio of the second EPSC amplitude to the first (15, 78). Only one neuron was recorded per slice, and at least four animals were used for each recording protocol.

Statistics. Detailed procedures for data and statistical analyses are described in the Supplemental Methods. Data are expressed as mean ± SEM. Sample sizes were based on previous studies and consistent with those generally used in the field (2, 3, 12, 15, 18, 19, 69). Because morphine-induced hyperalgesia, tolerance, and NMDAR hyperactivity were largely overlapping between male and female animals in this and prior studies (12, 19, 20), we combined the data from both groups. However, our study was not specifically powered to detect subtle sex-specific differences. One-way or 2-way ANOVA followed by Tukey’s or Dunnett’s post hoc tests were used to compare more than 2 groups. P < 0.05 was considered statistically significant.

Study approval. All experimental procedures were approved (approval #0882-RN03 and #1174-RN03) by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center and conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health).

Data availability. Values for all data points in figures are reported in the Supporting Data Values file. Data generated in this study are available from the corresponding author upon reasonable request.

Author contributions

DJ, HC, YH, and SRC performed research. DJ, SRC, and HLP analyzed data. DJ drafted the paper. SRC and HLP designed research and finalized the paper.

Conflict of interest

The authors have declared that no conflict of interest exists.

Funding support

This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central.

  • NIH grants DA041711 and NS101880 to HLP and SRC.
  • Pamela and Wayne Garrison Distinguished Chair Endowment to HLP.
Supplemental material

View Supplemental data

View Unedited blot and gel images

View Supporting data values

Acknowledgments

Human spinal cord tissues were obtained from the University of Maryland Brain and Tissue Bank, a NeuroBioBank Repository funded by the National Institutes of Health.

Address correspondence to: Hui-Lin Pan or Shao-Rui Chen, Department of Anesthesiology and Perioperative Medicine, Unit 110, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 832.817.8447; Email: huilinpan@mdanderson.org (HLP); schen@mdanderson.org (SRC).

Footnotes

Copyright: © 2026, Jin et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2026;136(17):e201808.https://doi.org/10.1172/JCI201808.

References
  1. Mao J, et al. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci. 1994;14(4):2301–2312.
    View this article via: CrossRef PubMed Google Scholar
  2. Chen SR, et al. Resistance to morphine analgesic tolerance in rats with deleted transient receptor potential vanilloid type 1-expressing sensory neurons. Neuroscience. 2007;145(2):676–685.
    View this article via: CrossRef PubMed Google Scholar
  3. Zhao YL, et al. Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: implications for opioid hyperalgesia and tolerance. J Biol Chem. 2012;287(30):25073–25085.
    View this article via: CrossRef PubMed Google Scholar
  4. Chia YY, et al. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth. 1999;46(9):872–877.
    View this article via: CrossRef PubMed Google Scholar
  5. Célèrier E, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology. 2000;92(2):465–472.
    View this article via: CrossRef PubMed Google Scholar
  6. Van Elstraete AC, et al. A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: the protective effect of prior administration of ketamine. Anesth Analg. 2005;101(6):1750–1756.
    View this article via: PubMed CrossRef Google Scholar
  7. Laulin JP, et al. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002;94(5):1263–1269, table of contents.
    View this article via: CrossRef PubMed Google Scholar
  8. Guignard B, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93(2):409–417.
    View this article via: CrossRef PubMed Google Scholar
  9. Stevens CW, Seybold VS. Changes of opioid binding density in the rat spinal cord following unilateral dorsal rhizotomy. Brain Res. 1995;687(1-2):53–62.
    View this article via: CrossRef PubMed Google Scholar
  10. Abbadie C, et al. Mu and delta opioid receptor-like immunoreactivity in the cervical spinal cord of the rat after dorsal rhizotomy or neonatal capsaicin: an analysis of pre- and postsynaptic receptor distributions. Brain Res. 2002;930(1-2):150–162.
    View this article via: CrossRef PubMed Google Scholar
  11. Sun J, et al. μ-Opioid receptors in primary sensory neurons are essential for opioid analgesic effect on acute and inflammatory pain and opioid-induced hyperalgesia. J Physiol. 2019;597(6):1661–1675.
    View this article via: CrossRef PubMed Google Scholar
  12. Chen SR, et al. Brief opioid exposure paradoxically augments primary afferent input to spinal excitatory neurons via α2δ-1-dependent presynaptic NMDA Receptors. J Neurosci. 2022;42(50):9315–9329.
    View this article via: CrossRef PubMed Google Scholar
  13. Barpujari A, et al. Role of peripheral sensory neuron mu-opioid receptors in nociceptive, inflammatory, and neuropathic pain. Reg Anesth Pain Med. 2020;45(11):907–916.
    View this article via: CrossRef PubMed Google Scholar
  14. Zeng J, et al. Primary afferent NMDA receptors increase dorsal horn excitation and mediate opiate tolerance in neonatal rats. J Neurosci. 2006;26(46):12033–12042.
    View this article via: CrossRef PubMed Google Scholar
  15. Zhou HY, et al. Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. J Neurosci. 2010;30(12):4460–4466.
    View this article via: CrossRef PubMed Google Scholar
  16. Deng M, et al. α2δ-1-Bound N-Methyl-D-aspartate receptors mediate morphine-induced hyperalgesia and analgesic tolerance by potentiating glutamatergic input in rodents. Anesthesiology. 2019;130(5):804–819.
    View this article via: CrossRef PubMed Google Scholar
  17. Deng M, et al. LRRC8A constitutively inhibits pain hypersensitivity in rodent models by restraining NMDA receptor activity at spinal cord synapses. Sci Transl Med. 2025;17(821):eadu4879.
    View this article via: CrossRef PubMed Google Scholar
  18. Deng M, et al. Mitogen-activated protein kinase signaling mediates opioid-induced presynaptic NMDA receptor activation and analgesic tolerance. J Neurochem. 2019;148(2):275–290.
    View this article via: CrossRef PubMed Google Scholar
  19. Jin D, et al. mGluR5 from primary sensory neurons promotes opioid-induced hyperalgesia and tolerance by interacting with and potentiating synaptic NMDA receptors. J Neurosci. 2023;43(31):5593–5607.
    View this article via: CrossRef PubMed Google Scholar
  20. Jin D, et al. Gαq signaling in primary sensory neurons shifts opioid analgesia to NMDA receptor-driven tolerance and hyperalgesia. Sci Signal. 2025;18(902):eadu8839.
    View this article via: CrossRef PubMed Google Scholar
  21. Belcheva MM, et al. Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem. 1998;70(2):635–645.
    View this article via: CrossRef PubMed Google Scholar
  22. Li LY, Chang KJ. The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors. Mol Pharmacol. 1996;50(3):599–602.
    View this article via: CrossRef PubMed Google Scholar
  23. Fukuda K, et al. Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. J Neurochem. 1996;67(3):1309–1316.
    View this article via: CrossRef PubMed Google Scholar
  24. Ignatova EG, et al. Requirement of receptor internalization for opioid stimulation of mitogen-activated protein kinase: biochemical and immunofluorescence confocal microscopic evidence. J Neurosci. 1999;19(1):56–63.
    View this article via: CrossRef PubMed Google Scholar
  25. Kramer HK, Simon EJ. mu and delta-opioid receptor agonists induce mitogen-activated protein kinase (MAPK) activation in the absence of receptor internalization. Neuropharmacology. 2000;39(10):1707–1719.
    View this article via: CrossRef PubMed Google Scholar
  26. Polakiewicz RD, et al. A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization. J Biol Chem. 1998;273(20):12402–12406.
    View this article via: CrossRef PubMed Google Scholar
  27. Nateri AS, et al. ERK activation causes epilepsy by stimulating NMDA receptor activity. EMBO J. 2007;26(23):4891–4901.
    View this article via: CrossRef PubMed Google Scholar
  28. Zhong J, et al. Raf kinase signaling functions in sensory neuron differentiation and axon growth in vivo. Nat Neurosci. 2007;10(5):598–607.
    View this article via: CrossRef PubMed Google Scholar
  29. Lim CS, et al. BRaf signaling principles unveiled by large-scale human mutation analysis with a rapid lentivirus-based gene replacement method. Genes Dev. 2017;31(6):537–552.
    View this article via: CrossRef PubMed Google Scholar
  30. Morice C, et al. Raf-1 and B-Raf proteins have similar regional distributions but differential subcellular localization in adult rat brain. Eur J Neurosci. 1999;11(6):1995–2006.
    View this article via: CrossRef PubMed Google Scholar
  31. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
    View this article via: CrossRef PubMed Google Scholar
  32. van den Bent MJ, et al. Primary brain tumours in adults. Lancet. 2023;402(10412):1564–1579.
    View this article via: CrossRef PubMed Google Scholar
  33. Blaukat A, et al. G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Galpha(q) and Galpha(i) signals. Mol Cell Biol. 2000;20(18):6837–6848.
    View this article via: CrossRef PubMed Google Scholar
  34. Della Rocca GJ, et al. Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of Gi- and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. J Biol Chem. 1997;272(31):19125–19132.
    View this article via: CrossRef PubMed Google Scholar
  35. O’Donovan KJ, et al. B-RAF kinase drives developmental axon growth and promotes axon regeneration in the injured mature CNS. J Exp Med. 2014;211(5):801–814.
    View this article via: CrossRef PubMed Google Scholar
  36. Kumar R, et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122(2):342–348.
    View this article via: CrossRef PubMed Google Scholar
  37. Michaloglou C, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720–724.
    View this article via: CrossRef PubMed Google Scholar
  38. Mjanger E, Yaksh TL. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. J Pharmacol Exp Ther. 1991;258(2):544–550.
    View this article via: CrossRef PubMed Google Scholar
  39. Zheng CF, Guan KL. Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. EMBO J. 1994;13(5):1123–1131.
    View this article via: CrossRef PubMed Google Scholar
  40. Khazak V, et al. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007;11(12):1587–1609.
    View this article via: CrossRef PubMed Google Scholar
  41. Marais R, et al. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem. 1997;272(7):4378–4383.
    View this article via: CrossRef PubMed Google Scholar
  42. Traynelis SF, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405–496.
    View this article via: CrossRef PubMed Google Scholar
  43. Li L, et al. α2δ-1 switches the phenotype of synaptic AMPA receptors by physically disrupting heteromeric subunit assembly. Cell Rep. 2021;36(3):109396.
    View this article via: CrossRef PubMed Google Scholar
  44. Zhou MH, et al. Spinal α2δ-1 induces GluA3 degradation to regulate assembly of calcium-permeable AMPA receptors and pain hypersensitivity. J Clin Invest. 2025;136(1):e193349.
    View this article via: JCI CrossRef PubMed Google Scholar
  45. Chen J, et al. The α2δ-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Rep. 2018;22(9):2307–2321.
    View this article via: CrossRef PubMed Google Scholar
  46. Zhou MH, et al. Protein kinase C-mediated phosphorylation and α2δ-1 interdependently regulate nmda receptor trafficking and activity. J Neurosci. 2021;41(30):6415–6429.
    View this article via: CrossRef PubMed Google Scholar
  47. Chen Y, et al. Increased α2δ-1-NMDA receptor coupling potentiates glutamatergic input to spinal dorsal horn neurons in chemotherapy-induced neuropathic pain. J Neurochem. 2019;148(2):252–274.
    View this article via: CrossRef PubMed Google Scholar
  48. Zhang GF, et al. α2δ-1 upregulation in primary sensory neurons promotes NMDA receptor-mediated glutamatergic input in resiniferatoxin-induced neuropathy. J Neurosci. 2021;41(27):5963–5978.
    View this article via: CrossRef PubMed Google Scholar
  49. Yeh TC, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576–1583.
    View this article via: CrossRef PubMed Google Scholar
  50. Cai YQ, et al. Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem. 2009;111(4):1000–1010.
    View this article via: CrossRef PubMed Google Scholar
  51. Laumet G, et al. G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition. Nat Neurosci. 2015;18(12):1746–1755.
    View this article via: CrossRef PubMed Google Scholar
  52. Chen AP, et al. Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory. J Neurosci Res. 2006;83(1):28–38.
    View this article via: CrossRef PubMed Google Scholar
  53. Lau J, et al. Temporal control of gene deletion in sensory ganglia using a tamoxifen-inducible Advillin-Cre-ERT2 recombinase mouse. Mol Pain. 2011;7:100.
    View this article via: CrossRef PubMed Google Scholar
  54. Bondzi C, et al. A novel assay for the measurement of Raf-1 kinase activity. Oncogene. 2000;19(43):5030–5033.
    View this article via: CrossRef PubMed Google Scholar
  55. de Freitas BG, et al. Mitogen-activated protein kinase signaling mediates morphine induced-delayed hyperalgesia. Front Neurosci. 2019;13:1018.
    View this article via: CrossRef PubMed Google Scholar
  56. Yao H, et al. Identification and characterization of small-molecule inhibitors to selectively target the DFG-in over the DFG-out conformation of the B-Raf kinase V600E mutant in colorectal cancer. Arch Pharm (Weinheim). 2016;349(10):808–815.
    View this article via: CrossRef PubMed Google Scholar
  57. Tahiri A, et al. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLoS One. 2013;8(8):e72692.
    View this article via: CrossRef PubMed Google Scholar
  58. Xie W, et al. Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids. Proc Natl Acad Sci U S A. 1999;96(18):10385–10390.
    View this article via: CrossRef PubMed Google Scholar
  59. Chen SR, et al. Increased spinal cord Na+-K+-2Cl– cotransporter-1 (NKCC1) activity contributes to impairment of synaptic inhibition in paclitaxel-induced neuropathic pain. J Biol Chem. 2014;289(45):31111–31120.
    View this article via: CrossRef PubMed Google Scholar
  60. Martinez Fiesco JA, et al. Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun. 2022;13(1):486.
    View this article via: CrossRef PubMed Google Scholar
  61. Varga A, et al. RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα. Sci Signal. 2017;10(469):eaai8482.
    View this article via: CrossRef PubMed Google Scholar
  62. Trakul N, et al. Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem. 2005;280(26):24931–24940.
    View this article via: CrossRef PubMed Google Scholar
  63. Clayton J, et al. Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors. Elife. 2025;13:RP95334.
    View this article via: CrossRef PubMed Google Scholar
  64. Songyang Z, et al. A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol. 1996;16(11):6486–6493.
    View this article via: CrossRef PubMed Google Scholar
  65. Granados-Soto V, et al. Spinal PKC activity and expression: role in tolerance produced by continuous spinal morphine infusion. Pain. 2000;85(3):395–404.
    View this article via: CrossRef PubMed Google Scholar
  66. Bilecki W, et al. Regulation of the extracellular signal-regulated kinases following acute and chronic opioid treatment. Cell Mol Life Sci. 2005;62(19-20):2369–2375.
    View this article via: CrossRef PubMed Google Scholar
  67. Husi H, et al. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci. 2000;3(7):661–669.
    View this article via: CrossRef PubMed Google Scholar
  68. Huang Y, et al. Calcineurin inhibition causes α2δ-1-mediated tonic activation of synaptic NMDA receptors and pain hypersensitivity. J Neurosci. 2020;40(19):3707–3719.
    View this article via: CrossRef PubMed Google Scholar
  69. Chen SR, Pan HL. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia. J Neurophysiol. 2006;95(5):3086–3096.
    View this article via: CrossRef PubMed Google Scholar
  70. Sun J, et al. μ-Opioid receptors in primary sensory neurons are involved in supraspinal opioid analgesia. Brain Res. 2020;1729(feb 15):146623.
    View this article via: CrossRef PubMed Google Scholar
  71. Kazmi SM, Mishra RK. Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (mu) and enkephalin (delta) binding sites. Biochem Biophys Res Commun. 1986;137(2):813–820.
    View this article via: CrossRef PubMed Google Scholar
  72. Yu VC, et al. A human neuroblastoma cell line expresses mu and delta opioid receptor sites. J Biol Chem. 1986;261(3):1065–1070.
    View this article via: CrossRef PubMed Google Scholar
  73. Lazarczyk M, et al. A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides. 2010;31(8):1606–1612.
    View this article via: CrossRef PubMed Google Scholar
  74. Pan HL, et al. Role of spinal NO in antiallodynic effect of intrathecal clonidine in neuropathic rats. Anesthesiology. 1998;89(6):1518–1523.
    View this article via: CrossRef PubMed Google Scholar
  75. Zhang J, et al. HDAC2 in primary sensory neurons constitutively restrains chronic pain by repressing α2δ-1 expression and associated NMDA receptor activity. J Neurosci. 2022;42(48):8918–8935.
    View this article via: CrossRef PubMed Google Scholar
  76. Huang Y, et al. NMDA receptors at primary afferent-excitatory neuron synapses differentially sustain chemotherapy- and nerve trauma-induced chronic pain. J Neurosci. 2023;43(21):3933–3948.
    View this article via: CrossRef PubMed Google Scholar
  77. Chen SR, et al. Calcineurin inhibitor induces pain hypersensitivity by potentiating pre- and postsynaptic NMDA receptor activity in spinal cords. J Physiol. 2014;592(1):215–227.
    View this article via: CrossRef PubMed Google Scholar
  78. Xie JD, et al. Presynaptic N-Methyl-d-aspartate (NMDA) receptor activity is increased through protein kinase C in paclitaxel-induced neuropathic pain. J Biol Chem. 2016;291(37):19364–19373.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (July 14, 2026): In-Press Preview
  • Version 2 (September 1, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Author contributions
  • Conflict of interest
  • Funding support
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts